Modiodal (Modafinil)

Modafinil, the active ingredient in Modiodal, is a eugeroic (wakefulness‑promoting agent) presented as an oral tablet for oral use. It is prescribed to improve daytime alertness in patients with certain sleep‑related disorders. It is indicated for conditions such as narcolepsy, obstructive sleep apnea‑related excessive daytime sleepiness, and shift work disorder, helping patients maintain functional wakefulness during the day.

GNH USA supplies Modiodal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality across global markets.

Modiodal (modafinil) acts on the central nervous system to promote wakefulness in sleep‑related disorders.

- Narcolepsy: reduces excessive daytime sleepiness and improves ability to stay awake. - Obstructive sleep apnea‑related excessive daytime sleepiness: alleviates residual sleepiness despite optimal apnea treatment. - Shift work disorder: helps maintain alertness during scheduled work hours that fall outside the normal sleep‑wake cycle.

Modiodal may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate throbbing headache often occurring within the first weeks of therapy. - Nausea: transient stomach upset or queasiness that usually resolves with continued use. - Insomnia: difficulty initiating or maintaining sleep, especially when taken later in the day. - Anxiety: heightened nervousness or feeling of restlessness. - Dry mouth: reduced salivation leading to a dry sensation in the mouth. - Dizziness: light‑headedness or vertigo, particularly upon standing quickly.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction characterized by blistering and detachment, requiring urgent medical care. - Cardiovascular events: chest pain, arrhythmias or sudden increase in blood pressure that may be life‑threatening.

Before prescribing Modiodal, clinicians should consider several safety aspects.

- Assess medical history: evaluate for cardiovascular disease, hypertension or psychiatric disorders before initiating therapy. - Monitor sleep patterns: ensure the drug is used for diagnosed sleep disorder and not for off‑label cognitive enhancement. - Caution in hepatic impairment: dose may need adjustment in patients with liver dysfunction. - Avoid abrupt discontinuation: taper under medical supervision to reduce risk of rebound sleepiness. - Pregnancy and lactation: safety not established; use only if potential benefit outweighs risk. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Modiodal can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can markedly increase modafinil plasma levels. - CYP2C19 inhibitors (e.g., fluvoxamine): may raise exposure and risk of adverse effects. - Anticonvulsants (e.g., carbamazepine, phenytoin): may reduce modafinil efficacy by increasing metabolism.

Moderate Interactions (Monitor Closely): - Oral contraceptives: modafinil may reduce hormonal contraceptive effectiveness; advise additional non‑hormonal methods. - Antidepressants (e.g., SSRIs, SNRIs): may increase risk of anxiety or insomnia. - Caffeine or other stimulants: additive central nervous system stimulation may exacerbate side effects.